Galapagos sees cystic fibrosis clinical trials in 2014
BRUSSELS Oct 17 (Reuters) - Belgian biotech company Galapagos said on Thursday that it was set to start clinical trials on a possible treatment for cystic fibrosis at the end of 2014.
The company said in a statement that it had developed a series of potentiators following laboratory tests and would be presenting its results at the North America Cystic Fibrosis Conference in Utah on Oct 17-19.
Galapagos said it would nominate a pre-clinical candidate by the end of this year, with first clinical trials set to start at the end of 2014.
Galapagos signed a cooperation deal last month worth up to $405 million with U.S. company AbbVie to develop a new treatment for cystic fibrosis.